Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
NCT05264974Phase 1Suspended
- Sponsor
- University of Florida
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma and soft tissue sarcoma (STS), sponsored by University of Florida. Primary endpoints: Maximum tolerated dose at 2 months and Feasibility of treatment with RNA-NP vaccine at 4 weeks. Started Mar 2026; status: suspended.
02
Conditions
melanomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05264974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05264974.